#eucrisa

Do not use EUCRISA if you are allergic to crisaborole or any of the ingredients in EUCRISA. See the end of this leaflet for a complete list of ingredients in EUCRISA.

Atopic Dermatitis” is a chronic, pruritic, inflammatory skin disease that often includes clinical features of skin dryness, erythema, oozing and crusting, and lichenification.

Eczema is a chronic inflammatory skin disease that affects nearly 18 million children and adults in the United States. Approximately 90% of the patients have mild to moderate symptoms.6,7 It is the most common atopic dermatitis (AD) skin disease, and it typically begins in childhood and lasts potentially throughout adulthood. The cause is unknown but believed to be a combination of genetic, immune and environmental factors. 6,7 Symptoms may include red, swollen, scaly and crusted bumps that can be extremely itchy. Scratching can worsen symptoms and can lead to swelling, cracking, and “weeping” clear fluid, which can coarsen and thicken the skin.6,7,9,10 AD is associated with multiple comorbidities, and has deleterious impacts on both individual and family quality of life. Some comorbidities include sleep impairment, asthma, allergic rhinitis, food allergies, and various cutaneous infections. 4 Over the past 15 years, no significant advances have been made in the treatment of atopic dermatitis. However, crisaborole has the potential to be an important first-line treatment option.

FDA-approved indication: Eucrisa is a phosphodiesterase 4 inhibitor indicated for topical treatment of mild to moderate atopic dermatitis in adult and pediatric patients 3 months of age and older (1). Topical corticosteroids are used in the management of atopic dermatitis in both adults and children and are the mainstay of anti-inflammatory therapy. Topical calcineurin inhibitors (TCI) are a second class of anti-inflammatory therapy.

The safety and effectiveness of EUCRISA have been established in pediatric patients ages 3 months and older for topical treatment of mild to moderate atopic dermatitis. Use of EUCRISA in this age group is supported by data from two 28-day adequate, vehicle controlled safety and efficacy trials which included 1,313 pediatric subjects ages 2 years to 17 years of whom 874 received EUCRISA. The most commonly reported adverse reaction in subjects 2 years and older was application site pain. Additionally, use of EUCRISA in pediatric patients ages 3 months to less than 2 years was supported by data from a 28 day open label, safety and pharmacokinetics (PK) trial in 137 subjects. No new safety signals were identified in subjects 3 months to less than 2 years of age.1

View On WordPress